热门资讯> 正文
Matinas BioPharma面临纽约证券交易所关于股权短缺的通知;直到2027年才能遵守
2026-06-27 05:38
- Matinas BioPharma (MTNB) announced on Friday that it received a notice from NYSE American for not meeting the exchange's minimum shareholder equity requirement.
- The company's shareholder equity fell to $3.02M in March 2026, below the required $4M threshold after posting losses for the past five years.
- The NYSE accepted the company's plan to resolve the issue and gave it until October 2, 2027, to regain compliance.
- Moreover, the shares could face delisting in the future if the company fails to improve its financial position.
- The notice does not impact the company's daily operations or stock trading for now.
- Source: Press Release
More on Matinas Biopharma
- Matinas BioPharma receives notice from NYSE
- Historical earnings data for Matinas Biopharma
- Financial information for Matinas Biopharma
推荐文章
一图看懂 | 营收增速创近三年新高！宁德时代营收、净利齐齐大增；A股史上最大回购！拟斥资200至400亿注销回购
美国总统特朗普推动科技巨头承诺自行承担AI数据中心新增电力成本
继黄仁勋后，AMD首席执行官苏姿丰表态支持开源AI模型
7月24日外盘头条：欧洲央行维持2.25%基准利率不变 英特尔Q2营收同比增长25% 摩根士丹利称日本国债值得买入
英特尔Q2营收同比增长25% GAAP转亏为盈与非GAAP表现超预期 资本开支增加
特斯拉二季度业绩不及预期引发股价下挫 做空者单日获利或超40亿美元
美股前瞻 | 油价疯涨逼近100美元关！谷歌绩后股价狂泄5%，马斯克再提特斯拉与SpaceX合并可能
Capex能否引爆半导体？谷歌、微软、Meta等接连放榜！五巨头财报有哪些看点？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
